LONDON, December 5, 2016 /PRNewswire/ --
BTG plc (LSE: BTG), the global specialist healthcare company,
today announces the inclusion of treatment with PneumRx®
Coils in guidelines for the management of chronic obstructive
pulmonary disease (COPD) published by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD). At the same time, the
French Ministry of Health has published its positive
recommendations regarding PneumRx® Coils on its
website.
(Logo:
http://photos.prnewswire.com/prnh/20150805/255981LOGO )
The updated GOLD guidelines now include endobronchial coils as a
minimally invasive, bronchoscopic approach to reducing
hyperinflation in severe emphysema patients. This update includes
coils as a therapy option for emphysema predominant patients with
severe hyperinflation, regardless of disease distribution or
presence of collateral ventilation.
The French Ministry of Health published its positive
recommendations regarding PneumRx® Coils on its website
as meeting an unmet medical need and fulfilling a public health
interest based on therapeutic improvement over optimal medical
therapy. This assessment will be a critical component in
determining national reimbursement for treatment of patients with
severe emphysema in France.
Both the GOLD recommendations and determination by the French
Ministry of Health are based on two multicenter randomized
controlled trials that examined the use of PneumRx®
Coils compared to usual care in changes in quality of life, lung
function and exercise capacity in patients with advanced
homogeneous and heterogeneous emphysema.
Guenter R. Janhofer, BTG Chief Medical Officer, commented:
"We're pleased that both GOLD and the French Ministry of Health
have acknowledged the value of PneumRx® Coils for
emphysema patients. In both randomized, controlled, multi-center
studies, patients treated with the PneumRx® Coil
experienced improvements in quality of life, lung function, and
exercise capacity. Data and imaging analysis is ongoing to further
consider best practices for patient selection. This analysis
will be shared in upcoming publications to provide additional
treatment considerations to physicians."
The GOLD report supports healthcare professionals worldwide to
implement effective COPD management programs based on quality of
evidence. The 2017 GOLD Report is the fourth major revision of
GOLD, incorporating an update of evidence reviewed by the global
scientific committee and a comprehensive reassessment of prior
recommendations for the diagnosis, assessment, and treatment of
COPD. For details visit: http://www.goldcopd.org.
The PneumRx® Coil is a shape-memory nitinol coil
implanted in the sub-segmental airways of the lung in patients with
severe emphysema via a minimally invasive bronchoscopic procedure.
For more information visit: http://www.pneumrx.com.
In Europe the
PneumRx® Coil has received CE Mark approval. The
endobronchial coil is currently limited to investigational use only
in the US. BTG is finalizing the regulatory submission to the FDA
for approval of endobronchial coils in the US.
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: http://www.btgplc.com.
For further information contact:
BTG
Andy Burrows, VP, Corporate &
Investor Relations
+44-(0)20-7575-1741; Mobile: +44-(0)7990-530-605
Stuart Hunt, Investor Relations
Manager
+44-(0)20-7575-1582; Mobile: +44-(0)7815-778-536
Chris Sampson, Corporate
Communications Director
+44-(0)20-7575-1595; Mobile:+44-(0)7773-251-178